Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

The Week in Review: AutekBio Raises $100 Million for Biologic CMO

publication date: Mar 13, 2010
 | 
author/source: Richard Daverman, PhD
It was a good week for fundings in China life science, with five companies announcing new capital. Chief among them was AutekBio, which released the news that it would take advantage of impressive $100 million for a biologic CMO facility.

AutekBio, Inc., with headquarters in the Bay Area of California but operations in China, will build Asia’s largest biologic CMO facility in southern Beijing (see story). To construct the facility, AutekBio signed a deal securing $100 million in venture capital from private and government sources. Contributing to the capital raise were SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, Beijing’s Municipal Government’s venture capital group.

Chongqing Porton Fine Chemicals Co., a CMO, raised $10 million from the Chongqing DT Fund (see story). The Chongqing DT Fund is a joint effort run by DT Capital of Shanghai and funded by the Chongqing Venture Capital Guidance Fund. Porton will use the money to build a state-of-the-art intermediate and API manufacturing facility in Changshou Chemical Park in Chongqing.

TCT Medical Technology, a China medical device company that focuses on the OB/GYN market, has raised $10 million in new capital from two Fidelity funds (see story). TCT claims to be the largest high-tech medical equipment and supplies importer in China within women’s health. It is the exclusive distributor in China of Cytyc’s ThinPrep pap test, the world’s leading cervical cancer screening product.

EA Inc., a company that makes invisible dental braces, completed a $6.6 million Series A financing led by OrbiMed, which provided “nearly all” of the funds, along with individual investors (see story). OrbiMed characterized the financing as a restructuring of EA Inc., which will move its official headquarters to the Cayman Islands, and its operations to Wuxi.

Lotus Pharmaceuticals (OTCBB: LTUS) (路坦制药有限公司) has begun construction of nine-storey building complex that will provide offices, R&D, production, and storage (see story). The new facility is being built on the grounds of its existing production facility in Beijing. Lotus, which has very low levels of cash, did not disclose the facility’s cost or the source of the funds for the project.

There was also some non-funding news in the China life science sphere during the week just past. Xiaochuan Wang, PhD, a returnee who founded Shanghai’s CRO Sundia MediTech (桑迪亚医药技术(上海)有限公司) in 2004, was named the Asia-Pacific Entrepreneur of the Year by BioSpectrum (see story). From its beginnings in 2004, Sundia has grown to an organization with 400 employees, including more than 300 scientists, which offers CRO services to over 90 customers from the US, Europe and Japan.

As expected, WuXi PharmaTech (NYSE: WX) (药明康德) reported 2009 net revenues of $270 million, an increase of 7% (see story). Net income climbed to $52.9 million, a great improvement from the loss of $64.2 million in 2008, caused in part by a writedown. In 2009, revenues matched analysts’ expectations, while earnings were slightly below forecasts.


Disclosure: none.





 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital